Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARK3 | P27448 | 3/20 | 0.34 |
| ▸ | JAK1 | P23458 | 4/20 | 0.33 |
| ▸ | JAK2 | O60674 | 10/20 | 0.32 |
| ▸ | JAK3 | P52333 | 8/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 7/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | ACP1 | P24666 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3300431 | 0.92 | JAK2 (0.42) | JAK2JAK3PTK2 | |
| SCHEMBL3298196 | 0.87 | JAK2 (0.31) | JAK1JAK2JAK3PTK2 | |
| SCHEMBL3304765 | 0.81 | JAK2 (0.33) | MARK3JAK1JAK2JAK3PTK2 | |
| SCHEMBL3308445 | 0.78 | JAK2 (0.33) | MARK3JAK2 | |
| SCHEMBL3308105 | 0.77 | GRM4 (0.30) | — | |
| SCHEMBL2145044 | 0.74 | JAK2 (0.37) | MARK3JAK1JAK2JAK3PTK2 | |
| SCHEMBL3306210 | 0.74 | FAAH (0.42) | JAK1JAK2JAK3PTK2SCN9A | |
| SCHEMBL2144254 | 0.68 | JAK2 (0.41) | JAK1JAK2JAK3PTK2 | |
| SCHEMBL2144553 | 0.67 | JAK2 (0.37) | JAK1JAK2JAK3PTK2 | |
| SCHEMBL2144549 | 0.67 | JAK2 (0.37) | JAK1JAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344494-B1 | AMINOTRIAZOLOPYRIDINES AND THEIR USE AS KINASE INHIBITORS | SIGNAL PHARM LLC (US) | 2016-04-20 | — | — | EP | disclosed |
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | BAHMANYAR SOGOLE (US) | 2013-01-03 | — | — | US | disclosed |
| US-8299056-B2 | Aminotriazolopyridines, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2012-10-30 | — | — | US | disclosed |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130005707-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | MARK3 618/4885JAK1 69/4885JAK2 26/4885 |
| US-20100093698-A1 | AMINOTRIAZOLOPYRIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | MAP3K2, MAP3K1, MAP3K3 | MARK3 618/4885JAK1 69/4885JAK2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.